Citigroup’s BIO-REFERENCE LABS INC-NEW- BRLI Stock Holding History

Citigroup’s Portfolio BRLI Stock Details BRLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-8,293	Closed	-$342K	–	8214
2015 Q2	$342K	Buy	8,293 +7,476	+915%	+$268K	﹤0.01%	4038
2015 Q1	$29K	Sell	817 -986	-55%	-$33.4K	﹤0.01%	5874
2014 Q4	$58K	Buy	1,803 +720	+66%	+$20.8K	﹤0.01%	5600
2014 Q3	$30K	Buy	1,083 +163	+18%	+$4.96K	﹤0.01%	5652
2014 Q2	$28K	Buy	920 +107	+13%	+$2.95K	﹤0.01%	5623
2014 Q1	$22K	Sell	813 -13,706	-94%	-$359K	﹤0.01%	5983
2013 Q4	$370K	Buy	14,519 +13,724	+1,726%	+$423K	﹤0.01%	4080
2013 Q3	$24K	Buy	795 +429	+117%	+$11.9K	﹤0.01%	5817
2013 Q2	$11K	Buy	+366	New	+$10.1K	﹤0.01%	6086

Other funds holding BRLI

SAM

Shell Asset Management The Hague, Netherlands $996M AUM 26.19% 1-Year Est. Return

Citigroup's BRLI Position: Q3 2015 in Review

Citigroup sold out of BIO-REFERENCE LABS INC-NEW- (BRLI) in Q3 2015, closing a stake of 8,293 shares — an estimated $342K sold.

Citigroup first reported a position in BRLI in Q2 2013 and held it in 9 quarters. The position peaked at $370K in Q4 2013. 1 fund tracked by Wall St. Rank holds BRLI as of Q3 2015.

Citigroup reported no remaining BIO-REFERENCE LABS INC-NEW- position as of Q3 2015 after selling out during the quarter.
Citigroup sold 8,293 BIO-REFERENCE LABS INC-NEW- shares in Q3 2015, an estimated $342K.
Citigroup first reported a position in BIO-REFERENCE LABS INC-NEW- in Q2 2013 and held it in 9 quarters.
Citigroup's BIO-REFERENCE LABS INC-NEW- position peaked at $370K in Q4 2013.
1 fund tracked by Wall St. Rank held BIO-REFERENCE LABS INC-NEW- as of Q3 2015.

Based on Citigroup's 13F filing for Q3 2015, filed 13 Nov 2015.